PZPatrizia Zappasodi

Patrizia Zappasodi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patrizia Zappasodi has a total of 467 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Favorable outcomes after early allogeneic stem cell transplantation in adult early T-cell precursor acute lymphoblastic leukemia treated with the pediatric-inspired GIMEMA LAL1913 program. A Campus ALL study

    by Gianluca Cavallaro, Davide Lazzarotto, Chiara Pavoni, Francesca Valsecchi, Anna Grassi, Marco Cerrano, Marzia Defina, Monia Lunghi, Fabio Giglio, Silvia Imbergamo, et al.

  • Open Access

    NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort

    by Calogero Vetro, Irene Azzali, Elisabetta Petracci, Cristina Papayannidis, Eleonora Eleuteri, Fanny Erika Palumbo, Vincenzo Federico, Nicola Fracchiolla, Patrizia Zappasodi, Maria Paola Martelli, et al.

    In the AVALON cohort of relapsed/refractory AML treated with venetoclax plus hypomethylating agents, NPM1 and IDH1/2 mutations showed no significant impact on response or survival. These findings indicate that prognostic models for relapsed AML should consider treatment context rather than baseline mutation status.


  • Top Cited Papers

    Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial

    by Uwe Platzbecker, Lionel Adès, Pau Montesinos, Emanuele Ammatuna, Pierre Fenaux, Claudia Baldus, Massimo Bernardi, Céline Berthon, Monica Bocchia, Caroline Bonmati, et al.

    PURPOSE: The phase III APOLLO trial prospectively compared the efficacy of arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) regimen (ATRA and ATO [ATRA-ATO]) plus low-dose idarubicin versus standard ATRA plus anthracycline-based chemotherapy (ATRA-CHT) regimen (ie, ATRA and idarubicin regimen) in patients with high-risk acute promyelocytic leukemia (APL; EudraCT 2015-01151-68; ClinicalTrials.gov identifier: NCT02688140 ). METHODS: Adult patients with newly diagnosed high-risk APL in the ATRA-ATO arm received ATO 0.15 mg/kg once daily and ATRA 45 mg/m 2 twice daily until complete remission (CR), with two doses of idarubicin 12 mg/m 2 on days 1 and 3, followed by consolidation therapy (four ATRA-ATO cycles). Patients in the ATRA-CHT arm received induction with ATRA 45 mg/m 2 twice daily and idarubicin 12 mg/m 2 once daily on days 1, 3, 5, and 7, followed by three cycles of chemotherapy-based consolidation and 2 years of maintenance therapy. The primary study end point was event-free survival (EFS) at 2 years. RESULTS: As of July 2022, 133 eligible patients had received either ATRA-ATO (n = 68) or ATRA-CHT (n = 65). The study was discontinued prematurely because of slow accrual during the COVID-19 pandemic. After a median follow-up of 37 months (range, 1.7-88.6 months), 2-year EFS was 88% in the ATRA-ATO arm and 71% in the ATRA-CHT arm (HR, 0.4 [95% CI, 0.17 to 0.92]; log-rank test P = .02). At a median of 7.8 and 12.1 months from achievement of CR, molecular relapse occurred in one (1.5%) ATRA-ATO patient versus eight (12.3%) ATRA-CHT patients ( P = .014). Overall, 32% and 68% of patients receiving ATRA-ATO and ATRA-CHT, respectively, reported serious treatment-emergent adverse events ( P < .01). CONCLUSION: The results of the APOLLO trial support the use of ATO and ATRA for the treatment of newly diagnosed patients with high-risk APL.


  • Open Access

    Real World Study on the Best CPX ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation

    by Fabio Guolo, Luana Fianchi, Maria Paola Martelli, Federico Lussana, Francesco Grimaldi, Federica Pilo, Michela Rondoni, Carla Filì, Paola Minetto, Debora Capelli, et al.

    In the registration clinical trial 301 (NCT01696084), CPX‐351 has shown to be superior to conventional 3 + 7 in secondary AML (s‐AML). However, the optimal duration of treatment, the best timing for allogeneic stem cell transplantation (allo‐HSCT), and the activity of CPX‐351 in specific s‐AML subgroups are unclear. To evaluate these aspects, a total of 513 s‐AML patients (median age 65.6 years, 19–79) treated with CPX‐351 were retrospectively analyzed. Complete remission (CR) rate after induction was 297/513 (58%), increasing to 340/513 (66%) after cycle 2. Among the 340 responding patients, 118 (34.7%), 137 (40.3%), and 85 (25%) received none, one, or two consolidation cycles of CPX‐351, respectively. Overall, 230/513 patients (48.8%) received allo‐HSCT. Median follow up was 23.66 months and median overall survival (OS) was 16.23 months. Patients with mutated NPM 1 or with ELN 2017 favorable risk ( p < 0.05) had a significantly longer OS ( p < 0.05). In a landmark analysis, receiving allo‐HSCT was associated with a longer survival (Median OS not reached vs. 16.3 months for patients receiving or not receiving allo‐HSCT, p < 0.05). Completion of all allowed CPX‐351 cycles was beneficial only in patients not proceeding to transplant ( p < 0.05), whereas in transplanted patients additional CPX‐351 cycles did not improve outcome. Our analysis suggests that also s‐AML patients with NPM1 mutations and those belonging to the ELN 2017 favorable risk category benefit from CPX‐351. In eligible patients, allo‐HSCT should be performed as soon as a CR is achieved, whereas patients not undergoing transplant benefit from a complete CPX‐351 schedule.


  • Open Access

    Real World Incidence and Etiology of Infectious Complications in Adults With Ph‐Negative Acute Lymphoblastic Leukemia Treated With the Pediatric‐Inspired GIMEMA LAL1913 Program. A Campus All Study

    by Patrizia Zappasodi, Ludovica Calabretta, Virginia Valeria Ferretti, Davide Lazzarotto, Nicola Fracchiolla, Marco Cerrano, Cristina Papayannidis, Sabina Chiaretti, Maria Ilaria Del Principe, Valentina Mancini, et al.

    Infections often complicate pediatric‐inspired treatments for adult Philadelphia‐negative acute lymphoblastic leukemia (Ph‐ ALL). Literature data on these complications are difficult to interpret due to the heterogeneity of types of infections analyzed or patients and treatment characteristics. A deeper insight on the infections occurring in the real life in uniformly treated ALL patients is lacking. This study investigated infectious complications in 240 newly diagnosed adult Ph‐ ALL patients treated in the real life according to the GIMEMA LAL1913 protocol by 18 Italian centers participating in the Campus ALL network. Incidence, etiology of microbiologically documented infections and invasive fungal infections (IFI) and mortality for infection were determined. Potential risk factors and the prophylactic strategies used during the first chemotherapy course (C1) were analyzed. Of 240 patients, 145 (60%) experienced at least one infectious episode, with bacterial infections being the most common (74.3%), followed by viral (13.9%), fungal (10.1%), and Pneumocystis jirovecii (1.7%) infections. The blood stream was the most involved site, pneumonia occurred in 14.6% of cases, half of which being fungal. Infections were prevalent during C1, affecting 40.5% of patients; IFI occurred in 12.5% of patients, most of them in C1. Risk factors for infections included older age (≥ 55 years and particularly > 65 years) and comorbidities only for IFI. The mortality rate for infection was 3.3%. Antibacterial, antiviral, antifungal, and anti‐PJ prophylaxis were variably administered and did not associate with a significant reduced infection rate. In conclusion, the rate of infectious complications in the real life of adult Ph‐ ALL patients treated with a pediatric‐inspired intensive regimen is high, mainly during induction and mostly bacterial, particularly in the bloodstream, with a high IFI rate. Older age, mainly over 65 years, is a risk factor for all types of infection. The antimicrobial prophylaxis was not associated to a reduced risk of infection.


  • Open Access

    Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents

    by Elisabetta Petracci, Giuseppe Lanzarone, Calogero Vetro, Maria Paola Martelli, Cristina Papayannidis, Ernesta Audisio, Paola Minetto, Carola Riva, Fabio Guolo, Gianluca Martini, et al.

    Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.


  • Open Access

    Unlocking Sanctuary Sites: The Efficacy of Brexucabtagene Autoleucel in Ocular B‐ALL Relapse

    by Ludovica Calabretta, Patrizia Zappasodi, Carlo Di Biase, Cristina Picone, Elisa Roncoroni, Marianna Rossi, Antonio Bianchessi, Irene Defrancesco, Caterina Zerbi, Beatrice Ferrari, et al.


  • Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial

    by Roberto Cairoli, Arianna Gatti, Giovanni Grillo, Marta Rachele Stefanucci, Barbara Di Camillo, Monica Fumagalli, Mauro Krampera, Gianpaolo Nadali, Patrizia Zappasodi, Erika Borlenghi, et al.

    Samples from 34 adult patients newly diagnosed with core binding factor leukemia (CBFL) were collected both at the time of diagnosis and at relapse and were centrally analyzed. Eligible patients received either standard induction CT known as "3 + 7" or an equivalent regimen, according to the recruiting center's policy. Patients who achieved CR or CRi received 3 courses of high-dose ARA-C (Cytarabine) 3000 mg/m2 every 12 h on days 1, 3, and 5, along with midostaurin at the dose of 50 mg b.i.d from Day 8 to Day 21 as part of consolidation therapy. Following the completion of the consolidation phase, patients received midostaurin as a monotherapy at the dose of 50 mg b.i.d. for 1 year as continuation therapy. The CR rate was 97%; we recorded an OS rate of 73.52% and a DFS rate of 48.4% for the entire cohort. The RI was 38.8% in the CBFB::MYH11 and 66.6% in the RUNX1::RUNX1T1 group. MRD (Measurable Residual Disease) was assessed by RQ-PCR at 10 time points throughout the study, as indicated by arrows.


  • Open Access

    Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study

    by Beatrice Manghisi, Lorenza Borin, Maria Rosaria Monaco, Gaia Giulia Angela Sacco, Laura Antolini, Raffaele Mantegazza, Monica Barichello, Umberto Mazza, Patrizia Zappasodi, Francesco Onida, et al.

    When a hematological malignancy is diagnosed, the whole family carries the burden of the disease; parents often try to protect minor children from suffering by avoiding communication about their disease. Since 2009, patients with minors at the Adult Hematology Division at San Gerardo Hospital (Monza) can take part in the “Emanuela Project”: children can visit parents and talk with psychologists and hematologists, who explain the disease through simple metaphors. The EMY STUDY aimed to evaluate the impact of illness-related communication on children’s behavior, comparing Monza’s experience with other Hematology Units, where the communication is delegated to parents or psychological support. Questionnaires exploring the children’s main behaviors (school performance, appetite, sleeping patterns, attachment to family figures, and family dialogue) were administered to both sick (SP) and healthy (HP) parents. From 2017 to 2021, 32 patients were enrolled, 20 from Monza and 12 from other hospitals; 84 questionnaires were globally collected. In Monza’s group, no major changes in children’s behavior were observed and an open dialogue about the disease was often possible. Disease communication is considered crucial and perceived as a responsibility of parents together with a professional figure, mainly the hematologist. Patients were satisfied with “Emanuela Project,” reporting positive effects on doctor-patient relationship. Difficulties in separation were significantly higher at other hospitals (P = .019) than in Monza. While at other centers communication is considered parents’ responsibility, Monza’s patients emphasize the role of professional figures (P = .007). Differently from other hospitals, the role of the hematologist is crucial to Monza’s patients (P = .001). Disease communication to patients’ offspring is a crucial moment in the process of care, and the hematologist can play a major role in this difficult task, with potential positive effects both on children’s well-being and on doctor-patient relationship.

  • Open Access

    Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda

    by Giuseppe Rossi, Erika Borlenghi, Patrizia Zappasodi, Federico Lussana, Massimo Bernardi, Claudia Basilico, Alfredo Molteni, Ivana Lotesoriere, Mauro Turrini, Marco Frigeni, et al.

    A retrospective survey was conducted in hematologic centres of the Rete Ematologica Lombarda (REL) on 529 older AML patients seen between 2020–2022. Compared to 2008–2016, the use of intensive chemotherapy (ICT) decreased from 40% to 18.1% and of hypomethylating agents (HMAs) from 19.5% to 13%, whereas the combination of Venetoclax/HMA, initially not available, increased from 0% to 36.7%. Objective treatment-specific fitness criteria proposed by SIE/SIES/GITMO in 2013 allow an appropriate choice between ICT and HMAs by balancing their efficacy and toxicity. Venetoclax/HMA, registered for patients unfit to ICT, has a unique toxicity profile because of prolonged granulocytopenia and increased infectious risk. Aiming at defining specific fitness criteria for the safe use of Venetoclax/HMA, a preliminary investigation was conducted among expert REL hematologists, asking for modifications of SIE/SIES/GITMO criteria they used to select candidates for Venetoclax/HMA. While opinions among experts varied, a general consensus emerged on restricting SIE/SIES/GITMO criteria for ICT-unfit patients to an age limit of 80–85, cardiac function > 40%, and absence of recurrent lung infections, bronchiectasis, or exacerbating COPD. Also, the presence of an adequate caregiver was considered mandatory. Such expert opinions may be clinically useful and may be considered when treatment-specific fitness criteria are updated to include Venetoclax/HMA.